News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

May 7, 2024

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)

The shareholders of Lipidor AB (publ) reg. no. 556779-7500 (the “Company”) are hereby given notice to attend the Annual General Meeting (the “AGM”) on 5 June 2024 at 09.00 CEST at Fredersen Advokatbyrå, Birger Jarlsgatan 8 in Stockholm. Registration starts at 08.30 CEST. NOTE: This is an unofficial translation of…

May 19, 2020

Lipidor publishes interim report for Q1 2020

Today, Lipidor AB publishes its interim report for the period January – March 2020. The Q1 report is available on the company's…

May 12, 2020

Lipidor publishes annual report for 2019

Today, Lipidor AB announces that the company will publish its annual report for the financial year 2019. The annual report is available…

May 11, 2020

NOTICE OF ANNUAL GENERAL MEETING OF LIPIDOR AB (publ)

The shareholders of Lipidor AB (publ) are hereby invited to attend the Annual General Meeting (the “AGM”) to be held on June…

May 7, 2020

Lipidor presents updated project plan – initiates Phase III study of AKP02 in-house

In light of the company's successful Phase III study of calcipotriol spray (AKP01) against mild to moderate plaque psoriasis and subsequent discussions…

March 4, 2020

New disinfection spray from Lipidor and Aurena Laboratories

In connection with the ongoing outbreak of Covid-19, caused by the new coronavirus, demand for disinfectants has snowballed and many products have…

February 25, 2020

Lipidor AB re-publishes year-end report for 2019

Yesterday, 24[ ]February at 4.59pm (CET), Lipidor AB (publ) published our year-end report for 2019 one day earlier than announced. We hereby re-publish the year-end report 2019 on the…

January 24, 2020

Lipidor announces positive topline results of AKP01 Phase III clinical study using calcipotriol spray against psoriasis

Lipidor AB (Nasdaq First North: LIPI) today reports positive topline results of its AKP01 Phase III clinical study, using calcipotriol spray against…

January 2, 2020

Lipidor AB (publ): The Knowledge Foundation funds collaborative project to study the effects of drug formulations on the skin barrier

Lipidor AB (Nasdaq First North: LIPI), in collaboration with Malmö University, MediGelium AB, Larodan AB and ERCO Pharma AB, has been awarded…

December 17, 2019

Lipidor AB (publ) updates timetable for results from ongoing phase III study – marginal shift in results reporting

Lipidor AB (Nasdaq First North: LIPI) today announces that results from the ongoing phase-III study, of calcipotriol spray against mild to moderate…

December 10, 2019

Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Lipidor AB (“Lipidor”), a Swedish topical drug development company, and Cannassure Therapeutics Ltd (“Cannassure”), an Israel based developer and producer of innovative…